534-51-0

Basic information

• Product Name: 3,5-DIIODO-DL-THYRONINE
• Synonyms: 3,5-DIIODO-DL-THYRONINE;2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodo-phenyl]-propanoic acid;2-Amino-3-[4-(p-hydroxyphenoxy)-3,5-diiodophenyl]propionic acid;2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodo-phenyl]propionic acid;2-azanyl-3-[4-(4-hydroxyphenoxy)-3,5-diiodo-phenyl]propanoic acid;DL-3,5-Diiodothyronine;DIIODO-L-THYRONINE, 3,5-(RG)(REQUEST QUOTE);DIIODO-L-THYRONINE, 3,5-(P)
• CAS NO: 534-51-0
• Molecular Formula: C₁₅H₁₃I₂NO₄
• Molecular Weight: 525.08
• Mol File: 534-51-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 250-252 °C
• Boiling Point: 559.4°Cat760mmHg
• Flash Point: 292.1°C
• Appearance: /
• Density: 2.095g/cm³
• PKA: 2.15±0.30(Predicted)
• CAS DataBase Reference: 3,5-DIIODO-DL-THYRONINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIIODO-DL-THYRONINE(534-51-0)
• EPA Substance Registry System: 3,5-DIIODO-DL-THYRONINE(534-51-0)

Safety Data

• Hazardous Substances Data: 534-51-0(Hazardous Substances Data)

Usage

General Description

3,5-DIIODO-DL-THYRONINE is a synthetic compound with chemical properties similar to the thyroid hormone, triiodothyronine (T3). It is also known as 3,5-diiodo-L-thyronine and is structurally similar to T3 but has different biological effects. 3,5-DIIODO-DL-THYRONINE has been studied for its potential role in regulating energy metabolism, improving lipid metabolism, and reducing body weight. It has been investigated as a potential treatment for obesity, metabolic syndrome, and related conditions. However, further research is needed to fully understand its effects and potential therapeutic applications.

Upstream product

• 3072-42-2 DL-N-Acetyl-3-<3,5-diiod-4-(4-methoxy-3-tert.-butyl-phenoxy)-phenyl>-2-amino-propionsaeure-ethylester 
• 2621-57-0 N-acetyl-O'-benzoyl-3,5-diiodo-L-thyronine ethyl ester 
• 21959-36-4 N-acetyl-3,5-diiodo-DL-tyrosine ethyl ester 
• 103-16-2 4-Benzyloxyphenol 
• 2944-48-1 2-tert-butylanisole 
• 2444-19-1 4-hydroxyphenyl benzoate 
• 2444-21-5 (4'-benzyloxyphenyl)benzoate 
• 29358-99-4 N-acetyl-3,5-dinitro-L-tyrosine ethyl ester 
• 2379-05-7 N-acetyl-O'-benzoyl-3,5-dinitro-L-thyronine ethyl ester 
• 60-18-4 L-tyrosine 
• 4190-01-6 Bis-<3-tert.-butyl-4-methoxy-phenyl>-iodonium-iodid 
• 123-31-9 hydroquinone 
• 94298-44-9 N-formyl-3,5-diiodo-L-thyronine 
• 54337-43-8 1-oxaspiro[2.5]octa-4,7-dien-6-one 

Downstream Products

• 94298-44-9 N-formyl-3,5-diiodo-DL-thyronine 
• 4299-88-1 3',5'-dibromo-3,5-diiodo-thyronine 
• 300-30-1 thyroxine 
• 1034-10-2 DL-thyronine 
• 16170-92-6 3-iodo-DL-thyronine 
• 3130-96-9 3,5,3'-Trijodothyronin (T₃) 
• 51-48-9 L-thyroxine 
• 6893-02-3 triiodothyronine 
• 1596-67-4 O-(4-hydroxyphenyl)-3,5-diiodo-L-tyrosine 
• 203585-45-9 3,5-diiodo-L-thyronine methyl ester 
• 3687-09-0 3,5-Diiodothyronamine 
• 2389-85-7 3,5-diiodo-4-(4-methoxy-phenoxy)-trans-cinnamic acid 
• 111149-73-6 3,5-diiodo-thyronine methyl ester; hydrochloride 
• 1549-09-3 N-Trifluoracetyl-3,5-diiod-DL-thyronin-ethylester 

Relevant articles and documents

Preparation method of levothyroxine sodium

The invention belongs to the field of pharmaceutical synthesis, and discloses a preparation method of levothyroxine sodium. The preparation method comprises the following steps: (1) taking 3,5-diiodo-L-tyrosine as a raw material, and preparing N-acetyl-L-tyrosine by firstly introducing acetyl protection to an amino group; (2) then preparing N-acetyl-3,5-diiodo-L-tyrosine ethyl ester under the action of thionyl chloride; (3) preparing N-acetyl-O-(4-methyoxyphenyl)-3,3-diiodo-L-tyrosine ethyl ester by carrying out Chan-Lam reaction through copper catalysis; (4) removing a protective group undera strong acidity condition, thus obtaining O-(4-hydroxyphenyl)-3,5-diiodo-L-tyrosine; (5) then reacting with iodine, and preparing O-(4-hydroxy-3,5-diiodo phenyl)-3,5-diiodo-L-tyrosine disodium salt under the action of sodium hydroxide; (6) finally, regulating pH (Potential of Hydrogen) through glacial acetic acid, thus obtaining the levothyroxine sodium. According to the preparation method disclosed by the invention, the key Chan-Lam reaction and other reaction steps are optimized, so that the reaction time can be greatly shortened, and the reaction yield can be increased; the preparation method is simple in technology, convenient to operate and suitable for industrial production.

Reductive dehalogenation and dehalogenative sulfonation of phenols and heteroaromatics with sodium sulfite in an aqueous medium

Prototropic tautomerism was used as a tool for the reductive dehalogenation of (hetero)aryl bromides and iodides, or dehalogenative sulfonation of (hetero)aryl chlorides and fluorides, using sodium sulfite as the sole reagent in an aqueous medium. This protocol does not require a metal or phase transfer catalyst and avoids using organic solvent as the reaction medium. This method is especially suitable for substrates that readily tautomerize (such as 2-or 4-halogenated aminophenols and 4-halogenated resorcinols), for which dehalogenation or sulfonation proceeds under mild reaction conditions (≤60 °C). As sodium sulfite is an inexpensive, safe, and environmentally less hazardous reagent, this method has at least three potential applications: (i) in the deprotection of halogens as protecting groups, using sodium sulfite as a reducing agent; (ii) in the sulfonation of aromatic halides under mild reaction conditions avoiding hazardous and corrosive reagents/solvents; and (iii) in the transformation of toxic halogenated aromatics into less harmful compounds.

PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE

The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3,5-diiodothyronine (3,5-T2), 3′,3-diiodothyronine (3′,3-T2), 3′,5-diiodothyronine (3′,5-T2), 3′-iodothyronine (3′-T), 3-iodothyronine (3-T) or 5-iodothyronine (5-T), in association with a pharmaceutically acceptable vehicle.